Bio-Rad Laboratories, Inc. (BIO) Stock AnalysisBIOStock AnalysisBio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bio-Rad Laboratories Inc is a good buy right now due to its current price of $387.7, which is near the analyst price target of $390, indicating potential upside. The company has shown a robust year-to-date change of +27.00% and a solid quarterly performance with a non-GAAP EPS of $2.62, exceeding expectations by $0.87. However, the main risk is the forward P/E ratio of 42.735, suggesting that the stock may be overvalued if growth does not continue as expected.

4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.